[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crohns-disease-active\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crohns-disease-active":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644522","tailored-anti-inflammatory-american-diet-for-patients-with-crohns-disease-100644522",false,"NCT07671872","Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease","Targeting Gut Inflammation Through Diet: a Tailored American Diet for Patients With Crohn's Disease","Inclusion Criteria:\n\n* Documented diagnosis with Crohn's Disease from medical records.\n* Ages 16-75\n* Mild to moderately active CD disease, defined by one of the following criteria:\n\nCrohn's disease activity index (CDAI) 150-250 (mild-to-moderate only active disease) AND presence of active inflammation either by: fecal calprotectin \\>150mg\u002Fdl. or radiologic findings of active ileal and\u002For colonic disease, or endoscopic findings showing active ileal and\u002For colonic disease within 4 weeks of baseline\n\n-On stable medications for their disease as or 3 months if medication is not listed\n\nExclusion Criteria:\n\n* Diagnosis of Ulcerative Colitis (UC).\n* Prior J pouch or diversion\n* Recent inflammatory bowel disease (IBD) related hospitalizations in the last 4 weeks\n* Clostridium difficile or enteric infections in the last 4 weeks\n* Use of probiotics in the last 4 weeks\n* Patients following the specific carbohydrate diet or Mediterranean diet or anti-inflammatory diet\n* Active cancer or conditions limiting their ability to follow a diet (heart failure, end stage renal disease)\n* Pregnancy, breastfeeding or planning to become pregnant during study period\n* Use of Total Parenteral Nutrition at the time of screening and during the study period\n* Other significant or life-threatening co-morbidities\n* The need for antibiotic use during the study period\n* Adults unable to consent\n* Ages \\\u003C 16 and \\> 75 years old\n* Prisoners\n* Crohn's specific complicated disease including active Stenotic (stricturing, B2) disease within the past 12 months, or Internal penetrating (B3) disease, or Draining perianal fistula, or Prior bowel resection\n* Patients with concomitant Celiac disease","ALL","16 Years","75 Years",{"count":20,"type":21},122,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to test the effect of an anti-inflammatory diet tailored for patients living in the United States with Crohn's Disease (CD) on clinical symptoms and disease inflammation and to identify biomarkers of response to dietary therapy.",[27,28,29],"Crohn's Disease, Active","Crohn's Disease (CD)","Diet Interventions","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":21},"2026-08",{"date":38,"type":21},"2030-08",{"name":40,"class":41},"University of Miami","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100620331","partial-enteral-nutrition-as-therapeutic-augmentation-of-advanced-pharmacological-therapy-in-patients-with-active-crohns-disease-100620331","NCT07356232","Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease","PANDORA","Inclusion Criteria:\n\n1. Ability to provide informed consent\n2. A confirmed diagnosis of Crohn's disease\n3. Plan to start one advanced Crohn's Disease therapy (anti-TNF, anti-IL12\u002FIL23, anti-IL23, anti-alpha 4 beta 7, JAK inhibitor).\n4. If taking aminosalyilates, methotrexate or thiopurines, participant must be on a stable does for at least 8 weeks prior to screening. Methotrexate, aminosalicylates and thiopurines are permitted to be continued with the advanced therapy if on stable dose for at least 8 weeks. Methotrexate or thiopurines may be initiated within 1 week of starting the advanced pharmacologic therapy\n5. Active disease defined by at least one of the criteria from group A AND one from group B.\n\nGroup A\n\n1. Short Crohn's Disease Activity Index (sCDAI) score \\>175, and if taking corticosteroids, dose cannot exceed 30 mg for prednisone or 9 mg for budesonide,\n2. sCDAI \\\u003C 175 and on 10- 30 mg of prednisone (or 6-9 mg of budesonide) at a stable dose for 2 weeks. Must have experienced worsening of symptoms with attempts to taper to a lower dose of steroids in 3 months prior to screening.\n\nGroup B\n\n1. Fecal calprotectin at baseline ≥ 300 ug\u002Fgr\n2. Active disease seen at colonoscopy within 8 weeks of the screening visit. Active disease requires presence of mucosal breaks including either diffuse scattered erosions or at least one ulcer (\\>5mm diameter)\n3. Active disease on cross-sectional imaging (CT scan, MRI or ultrasound) within 8 weeks of the screening visit (evidence of acute inflammation, such as ulceration or bowel wall thickening with restricted diffusion)\n\nExclusion Criteria:\n\n1. Pregnancy or breast feeding\n2. Presence of an ostomy\n3. Previous total colectomy\n4. Short gut syndrome from prior surgeries\n5. Consuming parenteral nutrition for more than 350 calories per day in the two weeks prior to screening\n6. Having been on the Crohn's Disease Exclusion Diet (CDED) in the 2 weeks prior to screening\n7. Plan to receive two simultaneously administered advanced therapies\n8. Planning to start a new medication in the same class as the medication currently taking. This does not include a switch from Ustekinumab to anti-IL23 drugs.\n9. Impending need for CD surgery per investigator\n10. Symptomatic stricture or stricture inducing bowel dilation (\\>3cm) as per local investigator.\n11. \\>4 very soft or liquid bowel movements per day when feeling well\n12. Diabetes mellitus requiring therapy with medication\n13. Known allergy to any ingredient in the Kate Farms formula.\n14. Unable to complete online surveys\n15. Unable to receive shipments of PEN formula.\n16. Starting a new medication for Crohn's disease other than steroids in the 8 weeks prior to the screening visit\n17. Has not consumed food in the last 6 days prior to screening\n18. Starting an accelerated (non-FDA approved) dose of advanced therapy\n19. At time of screening, participant is taking both Prednisone and Budesonide\n20. Untreated C. difficile infection with the last 8 weeks","18 Years","80 Years",{"count":53,"type":21},80,[24],"This is a multicenter non-randomized prospective open label trial of partial enteral nutrition (PEN) among patients with active Crohn's disease (CD) starting standard of care advanced therapy. Our central hypothesis is that combination therapy of PEN and pharmacologic therapy is more efficacious than pharmacologic therapy alone and can be well-tolerated for patients. Participants will choose to either include PEN along with starting their advanced therapy or will choose not to include PEN. 80 participants will be recruited from 15 sites across the United States.",[27],[58,59],"partial enteral nutrition","Crohn's disease exclusion diet","2026-02-24",{"date":62,"type":34},"2026-02-25",{"date":64,"type":21},"2026-04",{"date":66,"type":21},"2029-04",{"name":68,"class":41},"University of Pennsylvania",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":50,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":42},"100241474","visceral-sensitivity-in-ibd-irritable-bowel-disease-and-ibs-irritable-bowel-syndrome-100241474","NCT02421705","Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)","Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors","Inclusion Criteria:\n\nFor group 1: IBS\n\n1. Irritable Bowel Syndrome (IBS) (ROME III criteria)\n2. No obvious organic explanation for the IBS symptoms\n3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nGroup 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nGroup 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)\n\n1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)\n2. remission is confirmed by at least one sigmoidoscopy\n3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\n   Only for group 3a:\n4. Rome III criteria for IBS\n\nGroup 4: Healthy controls No abdominal (pain) complaints.\n\nGroup 5: active Crohn's disease\n\n1\\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nGroup 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)\n\n1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)\n2. remission is confirmed by at least one sigmoidoscopy\n3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study\n\nExclusion Criteria:\n\nFor all groups:\n\n1. co-morbidity: severe kidney- and\u002For liver disease or thyroid abnormalities and impaired clotting\n2. Abdominal chirurgy (except for an uncomplicated appendectomy)",true,"65 Years",{"count":79,"type":21},99999999,[24],"Aim:\n\nMore insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.",[83,84,85,86,27,87],"IBS","Ulcerative Colitis, Active","Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms)","Healthy Controls","Crohn's Disease, Remission (6a: With IBS Symptoms, 6b: Without IBS Symptoms)","RECRUITING","2023-02-07",{"date":91,"type":34},"2023-02-08",{"date":93,"type":4},"2010-02",{"date":95,"type":21},"2099-01",{"name":97,"class":41},"KU Leuven"]